Amarin Pharmaceuticals Inc.’s suit seeking a court order to allow it to tell doctors about the unapproved use of its fish oil pill Vascepa (icosapent) “is a frontal assault” on the framework for new drug approval, FDA contends.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?